| [1] |
XIE Mengsheng, ZHAO Yang, CHEN Feng.
Statistical analysis of active extension trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1007-1013.
|
| [2] |
WANG Zeng, YUAN Mei-qin, YANG Guo-nong, DING Hai-ying.
Clinical research progress of ACEI/ARB used in tumor treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 230-234.
|
| [3] |
HE Yan, WANG Liang-you.
Inhibitor of thrombin, bivalirudin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 339-343.
|
| [4] |
XIE Hai-tang, SUN Hua, LI Juan, TONG Jiu-cui, JIANG Si-yan, LI Hai-gang, PAN Hang-shan, JIA Yuan-wei, SUN Rui-yuan.
Application of covariance analysis in phase Ⅱ clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1240-1244.
|
| [5] |
XUE Jun, ZHOU Jian-dong, XIONG Ning-ning.
Commonly used SAS macro programs in blind data review of clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(5): 535-540.
|
| [6] |
HU Si-yuan, MA Rong, LIU Xiao-fan, XIANG Xi-xiong, DING Ying, HUANG Wen-yu, HUANG Zhi-jun, XIAO Fei.
Phase Ⅲ clinical trial of Xiaoeryiniao Granule on children with enuresis of kidney-qi deficiency in comparing with meclofenoxate hydrochlorid capsules
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 107-111.
|
| [7] |
LI Tao, GUO Lan.
Issues of clinical trails on traditional Chinese new drugs for diabetic poly-neuropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1401-1404.
|
| [8] |
LI Tao.
Some problems on clinical trails evalution of herbs medicine for insomnia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 375-378.
|
| [9] |
HUANG Yu-hong, WANG Bao-he, ZOU Shu-xuan, SUN Zeng-tao, SHANG Hong-cai, ZHANG Bo-li.
Risk management in clinical trails
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(11): 1215-1218.
|
| [10] |
HUANG Yu-hong, WANG Bao-he, ZOU Shu-xuan, SUN Zeng-tao, SHANG Hong-cai, ZHANG Bo-li.
Risk management in clinical trails
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(11): 1318-1320.
|
| [11] |
ZHAO Yang, YU Hao, LOU Dong-hua, LANG Su-ping, YI Hong-gang, CHEN Feng.
Generalized linear mixed models in multi-center crossover clinical trails
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(1): 116-120.
|
| [12] |
XIANG Nan, HU You-Zhi, SHI Jie, ZHANG Feng, FENG De-Xun.
Efficacy and safety of xindakang capsules in treatment of patients with angina pectoris
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(9): 1033-1036.
|
| [13] |
ZOU Jian-Dong, XIONG Ning-Ning, BO Qing-Yan, JIANG Meng, LIU Fang.
Designing of SAS macro program for statistic form of measurement data on normal distribution
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(7): 838-840.
|
| [14] |
XIONG Ning-Ning, LUO Mei, JIANG Meng, LIU Fang, ZHOU Jian-Dong, FU Wei-Min.
Design of indicated syndrome and its efficacy evaluation in clinical trial of TCM
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 715-717.
|
| [15] |
ZOU Jian-Dong, XIONG Ning-Ning, BO Qing-Yan.
OperatingProcedure and SASPrograms for data verification in clinical tri-als
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(5): 596-600.
|
